NKCL Bio Group
Inc. announced on the 3rd that it had obtained the 'T-5' grade, an excellent
company certification from the 'SCI’ Tech Credit Bureau, a technology credit
The Tech Credit
Bureau comprehensively analyzes and evaluates a company's technological
prowess, such as technology, marketability, business feasibility, and
management capability, and is divided into 10 grades from T-1 to T-10. The
‘T-4’ grade obtained by NKCL this time corresponds to the condition equivalent
to the KOSDAQ technology special listing, is a grade given to companies with
excellent technology and corresponds to the highest grade that small and
medium-sized enterprises can receive.
It is a very
rare case that a company like NKCL, who has been in business for 2 years, has
been selected, this technology evaluation has recognized the excellent
technology of NKCL Bio Group.
NKCL Bio Group
Inc., a leading biotech company, established in 2019 as a specialized brand for
'Personalized Immune Care', established NK cell culture technology and developed
a GMP automatic culture system capable of mass production of NK cell.
is continuously researching and developing NK cell therapeutics and immune care
products that can help boost immunity, centering on the keyword, immunity.
addition, it has patents and source technology for a medium addition kit and
culture method for NK cell, and is expanding its global marketing activities by
introducing various immune care products and bio programs such as bottled
water, health functional food, and cosmetics.
Shin, Dong-hwa said, “Currently, clinical trials for RK-NKTM anti-cancer
efficacy test and safety are in progress, and when clinical approval is
completed, we expect to receive a higher score in the valuation as a technology
company.” As we have been recognized for our technological progress and future
growth potential, we will continue to create a business model that enables
sustainable growth through expansion into various fields, such as investing in
R&D and nurturing talent to lead technology development in the future.”
added, “We plan to establish a full-fledged system so that CDMO for NK cell
therapy can proceed smoothly.”
NKCL Bio Group has won the NK cell therapy category at the '2022 National
Consumer-Centered Brand Grand Prize' hosted by the Dong-A Ilbo and won the
'2021 Future Creative Management Excellent Company Award' sponsored by the
Ministry of Employment and Labor and the Ministry of Science and ICT for two
consecutive years. It has a history of being objectively evaluated and
recognized for its efforts in the past.